Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 10/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.49 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.49 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.49 |
| ▸ | CCR2 | P41597 | 1/20 | 0.49 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.49 |
| ▸ | BLM | P54132 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.48 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5134779 | 1.00 | CXCR4 (0.55) | CXCR4MEN1CHRM2CHRM1ADRA2C | |
| SCHEMBL29223244 | 0.98 | CXCR4 (0.52) | CXCR4MEN1CHRM2CHRM1ADRA2C | |
| SCHEMBL935078 | 0.96 | SIGMAR1 (0.50) | CXCR4MEN1CHRM2CHRM1ADRA2C | |
| SCHEMBL2916592 | 0.96 | SIGMAR1 (0.50) | CXCR4MEN1CHRM2CHRM1ADRA2C | |
| SCHEMBL24177173 | 0.94 | SIGMAR1 (0.49) | CXCR4MEN1CHRM2CHRM1ADRA2C | |
| SCHEMBL13805257 | 0.92 | SIGMAR1 (0.48) | CXCR4MEN1CHRM2CHRM1ADRA2C | |
| SCHEMBL28997961 | 0.92 | CHRM5 (0.47) | CXCR4MEN1CHRM2CHRM1ADRA2C | |
| SCHEMBL22398868 | 0.91 | SIGMAR1 (0.46) | CXCR4MEN1CHRM2CHRM1ADRA2C | |
| SCHEMBL8675042 | 0.90 | CHRM5 (0.49) | CXCR4MEN1CHRM2CHRM1ADRA2C | |
| Pyrrolidine SCHEMBL4661508 | 0.90 | CHRM5 (0.52) | CXCR4MEN1CHRM2CHRM1ADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4719486-A1 | CONJUGATES AND USES THEREOF | Full-Life Technologies UK Limited (GB) | 2026-04-08 | — | — | EP | claimed |
| EP-4719498-A1 | RADIOLIGANDS FOR TARGETING CELL SURFACE RECEPTORS AND USES THEREOF | Full-Life Technologies UK Limited (GB) | 2026-04-08 | — | — | EP | claimed |
| WO-2025199636-A1 | TARGETED RADIOLIGAND COMPOUNDS AND USES THEREOF | MCMASTER UNIVERSITY (CA) | 2025-10-02 | — | — | WO | claimed |
| EP-4619411-A1 | DUAL RECEPTOR TARGETING RADIOLIGANDS AND USES THEREOF | Full-Life Technologies HK Limited (HK) | 2025-09-24 | — | — | EP | claimed |
| EP-4556029-A2 | RADIOPHARMACEUTICAL CONJUGATE | The South African Nuclear Energy Corporation Limited (ZA) | 2025-05-21 | — | — | EP | claimed |
| US-20250099632-A1 | CLEAVABLE RADIOLIGANDS FOR TARGETING CELL SURFACE RECEPTORS AND USES THEREOF | FULL-LIFE TECHNOLOGIES UK LIMITED (GB) | 2025-03-27 | — | — | US | claimed |
| US-20250026739-A1 | COMPOUNDS AND RADIOLIGANDS FOR TARGETING NEUROTENSIN RECEPTOR AND USES THEREOF | FULL-LIFE TECHNOLOGIES HK LIMITED (CN) | 2025-01-23 | — | — | US | claimed |
| EP-4479040-A1 | COMPOUNDS AND RADIOLIGANDS FOR TARGETING NEUROTENSIN RECEPTOR AND USES THEREOF | Full-Life Technologies HK Limited (HK) | 2024-12-25 | — | — | EP | claimed |
| WO-2024245421-A1 | RADIOLIGANDS FOR TARGETING CELL SURFACE RECEPTORS AND USES THEREOF | FULL-LIFE TECHNOLOGIES HK LIMITED (CN) | 2024-12-05 | — | — | WO | claimed |
| WO-2024245407-A1 | CONJUGATES AND USES THEREOF | FULL-LIFE TECHNOLOGIES HK LIMITED (CN) | 2024-12-05 | — | — | WO | claimed |
| US-20190175750-A1 | COMPOSITION AND METHOD FOR MODIFYING POLYPEPTIDES | ADVANCED PROTEOME THERAPEUTICS INC. | 2019-06-13 | — | — | US | claimed |
| EP-2453927-B1 | LOADING TECHNIQUE FOR PREPARING RADIONUCLIDE AND IONOPHORE CONTAINING LIPOSOMES IN WHICH THE IONOPHORE IS 2-HYDROXYQUIONOLINE (CARBOSTYRIL) OR STRUCTURALLY RELATED 2-HYDROXYQUINOLINES | UNIV DENMARK TECH DTU (DK) | 2019-05-15 | — | — | EP | claimed |
| EP-2651447-B1 | ENTRAPMENT OF RADIONUCLIDES IN NANOPARTICLE COMPOSITIONS | UNIV DENMARK TECH DTU (DK) | 2018-08-29 | — | — | EP | claimed |
| US-20170296684-A1 | RADIOPHARMACEUTICAL CONJUGATE | UNIVERSITY OF CAPE TOWN (ZA) | 2017-10-19 | — | — | US | claimed |
| US-20160158392-A1 | Entrapment of Radionuclides in Nanoparticle Compositions | RIGSHOSPITALET (DK) | 2016-06-09 | — | — | US | claimed |
| US-9226984-B2 | Entrapment of radionuclides in nanoparticle compositions | Technical University of Denmark and Rigshospitalet (DK) | 2016-01-05 | — | — | US | claimed |
| US-8920775-B2 | Loading technique for preparing radionuclide containing nanoparticles | TECHNICAL UNIVERSITY OF DENMARK (DK) | 2014-12-30 | — | — | US | claimed |
| US-20130251630-A1 | Entrapment of Radionuclides in Nanoparticle Compositions | RIGSHOSPITALET (DK) | 2013-09-26 | — | — | US | claimed |
| US-20120213698-A1 | LOADING TECHNIQUE FOR PREPARING RADIONUCLIDE CONTAINING NANOPARTICLES | RIGSHOSPITALET (DK) | 2012-08-23 | — | — | US | claimed |
| EP-2453927-A1 | LOADING TECHNIQUE FOR PREPARING RADIONUCLIDE AND IONOPHORE CONTAINING LIPOSOMES IN WHICH THE IONOPHORE IS 2-HYDROXYQUIONOLINE (CARBOSTYRIL) OR STRUCTURALLY RELATED 2-HYDROXYQUINOLINES | Technical University of Denmark (DK) | 2012-05-23 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250026739-A1 | COMPOUNDS AND RADIOLIGANDS FOR TARGETING NEUROTENSIN RECEPTOR AND USES THEREOF | NTSR1, NTSR2, NPSR1 | CXCR4 447/4885MEN1 281/4885CHRM2 835/4885 |
| US-20250099632-A1 | CLEAVABLE RADIOLIGANDS FOR TARGETING CELL SURFACE RECEPTORS AND USES THEREOF | ASGR1, GNRHR, SCTR | CXCR4 641/4885MEN1 842/4885CHRM2 1767/4885 |
| US-20190175750-A1 | COMPOSITION AND METHOD FOR MODIFYING POLYPEPTIDES | PTMS, SRMS, ACP1 | CXCR4 1899/4885MEN1 1660/4885CHRM2 3509/4885 |
| US-20120213698-A1 | LOADING TECHNIQUE FOR PREPARING RADIONUCLIDE CONTAINING NANOPARTICLES | LIPG, NPC1L1, CD47 | CXCR4 790/4885MEN1 154/4885CHRM2 4748/4885 |
| US-20170296684-A1 | RADIOPHARMACEUTICAL CONJUGATE | FOLH1, EPRS1, FOLR1 | CXCR4 571/4885MEN1 244/4885CHRM2 2386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.